Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Shengtai Pharmaceutical Inc (PK:SGTI)

Business Focus: Generic Pharmaceuticals

Sector:  Healthcare Industry:  Pharmaceuticals
 
Company Contact
Address: Changda Road East
Development District, Changle County
WEIFANG SDG 262400
Tel: N/A
Website: N/A
IR: N/A
Key People
Qingtai Liu
Chairman of the Board, Chief Executive Officer
Yongqiang Wang
Chief Financial Officer, Director
 
Business Overview
Shengtai Pharmaceutical, Inc. (Shengtai), through its wholly owned subsidiary, Weifang Shengtai Pharmaceutical Inc., is a producer of pharmaceutical-grade glucose in China. The Company's products include pharmaceutical-grade glucose or dextrose, used for medical purposes, as well as other glucose and cornstarch products used for the food and beverage industry, and for industrial productions in China. The Company's glucose series include dextrose monohydrate (DMH), dextrose anhydrous, oral glucose dextrin and rough glucose for other processing purposes. Its starch series include pharmaceutical starch and edible corn starch. The Company's customers include healthcare institutions, food and beverage companies, pharmaceutical companies, medical supply exporters and medical supply. The Company also exports its products to approximately 70 different countries overseas, such as Japan, Singapore, Korea, Australia, Russia and India.
Financial Overview
For the nine months ended 31 March 2013, Shengtai Pharmaceutical Inc revenues increased 32% to $162.6M. Net income decreased 39% to $563K. Revenues reflect International segment increase of 78% to $11.8M, China segment increase of 14% to $38M. Net income was offset by SELLING, GENERAL AND ADMINISTRATIVE EXP increase of 31% to $11.1M (expense), Non-operating income decrease of 93% to $51K (income).